A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

CompletedOBSERVATIONAL

Enrollment

376

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions

Carcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

as provided in real world practice

Trial Locations (1)

Pfizer, Istanbul